Arrow Financial’s Ginkgo Bioworks DNA Stock Holding History

Arrow Financial’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$16	–	205
2024 Q3	$16	Buy	+2	New	+$20	﹤0.01%	340

Other funds holding DNA

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Arrow Financial's DNA Position: Q4 2024 in Review

Arrow Financial sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 2 shares — an estimated $16 sold.

Arrow Financial first reported a position in DNA in Q3 2024 and held it in 1 quarter. The position peaked at $16 in Q3 2024. 165 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

Arrow Financial reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
Arrow Financial sold 2 Ginkgo Bioworks shares in Q4 2024, an estimated $16.
Arrow Financial first reported a position in Ginkgo Bioworks in Q3 2024 and held it in 1 quarter.
Arrow Financial's Ginkgo Bioworks position peaked at $16 in Q3 2024.
165 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on Arrow Financial's 13F filing for Q4 2024, filed 14 Feb 2025.